George Adam D. 4

Accession 0000899243-21-002559

CIK 0001351288other

View on SEC.gov Company Profile

Filed

Jan 19, 7:00 PM ET

Accepted

Jan 20, 8:00 PM ET

Size

25.5 KB

Accession

0000899243-21-002559

Insider Transaction Report

Form 4

Period: 2021-01-15

GW PHARMACEUTICALS PLCGWPH

George Adam D.

Secretary

Transactions

Exercise/Conversion
Ordinary Shares
2021-01-15$10.61/sh+25,716$272,847→ 35,716 total
Exercise/Conversion
Share Options
2021-01-15−1,584→ 48,888 total
Exercise: $9.61From: 2020-12-31Exp: 2028-02-26→ Ordinary Shares (1,584 underlying)
Exercise/Conversion
Ordinary Shares
2021-01-15$9.81/sh+52,560$515,614→ 88,276 total
Sale
Ordinary Shares
2021-01-15$11.72/sh−53,376$625,567→ 36,484 total
Sale
Ordinary Shares
2021-01-15$11.75/sh−26,484$311,187→ 10,000 total
Exercise/Conversion
Share Options
2021-01-15−52,560→ 0 total
Exercise: $9.81From: 2020-01-06Exp: 2027-01-06→ Ordinary Shares (52,560 underlying)
Exercise/Conversion
Ordinary Shares
2021-01-15$9.61/sh+1,584$15,222→ 89,860 total
Exercise/Conversion
Ordinary Shares
2021-01-19$9.61/sh+9,600$92,256→ 19,600 total
Exercise/Conversion
Share Options
2021-01-15−25,716→ 4 total
Exercise: $10.61From: 2018-06-24Exp: 2025-06-24→ Ordinary Shares (25,716 underlying)
Exercise/Conversion
Share Options
2021-01-15−9,600→ 39,288 total
Exercise: $9.61From: 2020-12-31Exp: 2028-02-26→ Ordinary Shares (9,600 underlying)
Sale
Ordinary Shares
2021-01-19$11.68/sh−9,600$112,128→ 10,000 total

Footnotes (7)

[F1]Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares of ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.
[F2]The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020.
[F3]Represented by ADSs.
[F4]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($140.67 per ADS). These shares were sold in multiple transactions at prices ranging from $140.00 per ADS (or $11.67 per ordinary share) to $140.87 per ADS (or $11.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F5]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($141.04 per ADS). These shares were sold in multiple transactions at prices ranging from $141.11 per ADS (or $11.76 per ordinary share) to $141.61 per ADS (or $11.80 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F6]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($140.15 per ADS). These shares were sold in multiple transactions at prices ranging from $140.04 per ADS (or $11.67 per ordinary share) to $140.83 per ADS (or $11.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F7]Accelerated due to retirement of the reporting person.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

GW PHARMACEUTICALS PLC

CIK 0001351288

→

Entity typeother

Related Parties

filerCIK 0001754239

Filing Metadata

Form type: 4
Filed: Jan 19, 7:00 PM ET
Accepted: Jan 20, 8:00 PM ET
Size: 25.5 KB

View on SEC.gov